Self-assembled micelles based on gambogenic acid-phospholipid complex for sustained-release drug delivery

Wang, Beilei; Cheng, Weiye; Zhang, Caiyun; Bao, Youmei; Zha, Liqiong; Qian, Jiajia; Hong, Lufeng; Chen, Weidong

doi:10.1080/02652048.2019.1656294

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The encapsulation efficiency (EE %) of GNA@PDA-FA SA NPs was investigated by the ultrafiltration method according to our previous studies. , Briefly, 1 mL of the GNA@PDA-FA SA NP solution was injected to an ultrafiltration tube followed by centrifugation at 1711 g for 10 min. Free GNA molecules passed through the filter membrane and was collected from the outer tube, whereas GNA@PDA-FA SA NPs were successfully cut off by the membrane.…”

Section: Methodsmentioning

confidence: 99%

Oral Delivery of Gambogenic Acid by Functional Polydopamine Nanoparticles for Targeted Tumor Therapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

To enhance the water solubility, oral bioavailability, and tumor targeting of gambogenic acid (GNA), polydopamine nanoparticles (PDA NPs) were prepared to encapsulate and stabilize GNA surface modified by folic acid (FA) and then coated with sodium alginate (GNA@PDA-FA SA NPs) to achieve an antitumor effect by oral administration. GNA@PDA-FA SA NPs exhibited in vitro pH-sensitive release behavior. In vitro cell studies manifested that GNA@PDA-FA NPs had higher cytotoxicity to 4T1 cells compared with raw GNA (IC 50 = 2.58 μM vs 7.57 μM). After being modified with FA, GNA@PDA-FA NPs were taken up easily by 4T1 cells. In vivo studies demonstrated that the area under the curve (AUC 0→∞ ) of the plasma drug concentration−time of GNA@ PDA-FA SA NPs was 2.97-fold higher than that of raw GNA, along with improving drug distribution in the liver, lung, and kidney tissues. In vivo anti-tumor experiments, GNA@PDA-FA SA NPs significantly inhibited the growth of breast tumors in the 4T1 xenograft breast cancer model via oral administration without obvious toxicity on major organs. Our studies indicated that the GNA@PDA-FA SA NPs modified with FA and coated with SA were a promising drug delivery system for targeting tumor therapy via oral administration.

show abstract

Section: Methodsmentioning

confidence: 99%

Oral Delivery of Gambogenic Acid by Functional Polydopamine Nanoparticles for Targeted Tumor Therapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lin et al [66] demonstrated that GNA-loaded mixed polymeric micelles (GNA-MMs) featured a small size and high entrapment efficiency and maintained the cytotoxicity of GNA on HepG2 cells. Wang et al [96] presented GNA-phospholipid complex (GNA-PLC) micelles. GNA has a higher cytotoxic effect on HepG2 cells after forming GNA-PLC micelles.…”

Section: Drug Delivery System Of Gambogenic Acid In Cancersmentioning

confidence: 99%

Unveiling Gambogenic Acid as a Promising Antitumor Compound: A Review

Mi,

Xing,

Zhang

et al. 2024

Planta Med

View full text Add to dashboard Cite

Gambogenic acid is a derivative of gambogic acid, a polyprenylated xanthone isolated from Garcinia hanburyi. Compared with the more widely studied gambogic acid, gambogenic acid has demonstrated advantages such as a more potent antitumor effect and less systemic toxicity than gambogic acid according to early investigations. Therefore, the present review summarizes the effectiveness and mechanisms of gambogenic acid in different cancers and highlights the mechanisms of action. In addition, drug delivery systems to improve the bioavailability of gambogenic acid and its pharmacokinetic profile are included. Gambogenic acid has been applied to treat a wide range of cancers, such as lung, liver, colorectal, breast, gastric, bladder, and prostate cancers. Gambogenic acid exerts its antitumor effects as a novel class of enhancer of zeste homolog 2 inhibitors. It prevents cancer cell proliferation by inducing apoptosis, ferroptosis, and necroptosis and controlling the cell cycle as well as autophagy. Gambogenic acid also hinders tumor cell invasion and metastasis by downregulating metastasis-related proteins. Moreover, gambogenic acid increases the sensitivity of cancer cells to chemotherapy and has shown effects on multidrug resistance in malignancy. This review adds insights for the prevention and treatment of cancers using gambogenic acid.

show abstract

Phospholipid Complex Formulation Technology for Improved Drug Delivery in Oncological Settings: a Comprehensive Review

Patil,

Pawde,

Bhattacharya

et al. 2024

AAPS PharmSciTech

View full text Add to dashboard Cite

Self-assembled micelles based on gambogenic acid-phospholipid complex for sustained-release drug delivery

Cited by 4 publications

References 36 publications

Oral Delivery of Gambogenic Acid by Functional Polydopamine Nanoparticles for Targeted Tumor Therapy

Oral Delivery of Gambogenic Acid by Functional Polydopamine Nanoparticles for Targeted Tumor Therapy

Unveiling Gambogenic Acid as a Promising Antitumor Compound: A Review

Phospholipid Complex Formulation Technology for Improved Drug Delivery in Oncological Settings: a Comprehensive Review

Contact Info

Product

Resources

About